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Abstract 
Hemorrhage is a rare complication of acute cholecystitis. Patients who develop this 
complication often are receiving anticoagulation therapy or have a pathologic 
coagulopathy. We present a case of an elderly patient who developed hemorrhagic 
cholecystitis while taking aspirin and cilostazol, a phosphodiesterase inhibitor. The 
patient underwent an emergent abdominal exploration. A large, blood-filled gallbladder 
was found along with a large hematoma between the liver and gallbladder. We also 
briefly review the literature regarding hemorrhagic cholecystitis, hemorrhage into the 
biliary tree, and hemorrhage as a complication of aspirin and phosphodiesterase 
inhibitor therapy. 
 
Case Report 
A 91-year-old woman presented to our emergency department with a 20-hour history of vague 
right-sided abdominal pain that was not associated with meals. She experienced nausea and vomiting 
without hematemesis. She had no change in her bowel movements and no melena. 
The patient had a complex medical history, including a hospitalization for an exacerbation of 
congestive heart failure and pneumonia several months prior. She did not have a history of bleeding 
tendencies and no recent changes had been made to her daily medications. She had been taking 
cilostazol, a phosphodiesterase inhibitor, for the previous 4 years for lower extremity claudication and 
aspirin (325 mg) for the previous 9 years for cardiovascular protective effects. 
She was afebrile with a pulse of 86 beats per minute, blood pressure of 119/64 mm Hg, respirations 
of 18 breaths per minute, and oxygen saturation of 93% on room air. Her abdominal exam 
demonstrated right supraumbilical tenderness without involuntary guarding or rebound tenderness. 
Her leukocyte count was 18.1 × 10
9/l, and her hemoglobin was 12.1 g/dl. Liver function tests, including 
AST, and total and direct bilirubin were normal, as were the patient’s INR and aPTT. She was typed and 
crossed for 2 units of packed red blood cells but did not require transfusion of blood or platelets.  
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The abdominal radiograph demonstrated no free intraabdominal air. A CT scan revealed 
inflammatory changes in the pericholecystic fat and gallbladder fossa, and IV contrast within the 
gallbladder lumen. IV contrast was also found in a small amount of free fluid around the liver. These 
findings were considered worrisome for hemorrhagic cholecystitis with perforation (fig. 1). 
The patient was admitted to the surgical ICU for preoperative volume resuscitation. The aspirin and 
cilostazol were stopped. Given the patient’s medical comorbidities, a cholecystostomy tube was initially 
considered. However, we recommended an urgent abdominal exploration because of the intraperitoneal 
hemorrhage. 
The abdomen was explored via a right subcostal incision. Inspection of the right upper quadrant 
revealed approximately 350 ml of blood. The gallbladder was intact yet necrotic and contained a large 
hematoma and countless 1- to 2-mm stones (fig. 2). Histology demonstrated acute hemorrhagic 
cholecystitis with cholelithiasis. After removal of the gallbladder, the abdomen was copiously irrigated 
with warm normal saline. No other abnormalities were found. 
The patient recovered in the ICU for six days after the operation before being transferred to the 
floor. She experienced no postoperative bleeding episodes. She was discharged on postoperative day 21 
after a hospital course which was dominated by the care of her medical comorbidities. Aspirin therapy 
was reinitiated uneventfully by her primary care physician at a lower dose (81 mg) two months after this 
episode. The cilostazol was discontinued. 
Discussion 
Hemorrhage is a rare complication of acute cholecystitis. The mechanism is felt to be 
due to a transmural inflammatory process that causes erosion of the mucosa and 
ischemia. These processes then cause further mucosal breakdown, erosion into 
gallbladder vessels, and subsequent hemorrhage into the gallbladder lumen or the 
abdominal cavity [1]. We believe our patient experienced this same sequence of events, 
leading to her presentation. 
Hemorrhage into the gallbladder lumen may occur for a variety of reasons, including 
obstructive cholecystitis, trauma, percutaneous interventions, biliary neoplasms, biliary 
parasites, or bleeding disorders. Our patient did not have a specific bleeding disorder; 
however, she was taking both aspirin and cilostazol, which create irreversible and 
reversible inhibition of platelet function, respectively. Several reports that link 
coagulopathy and hemorrhagic cholecystitis have been published [2–4]. Arteriosclerosis is 
thought to be a predisposing factor for gallbladder hemorrhage [5]. 
The patient with hemorrhage into the gallbladder may present in a variety of ways. The 
blood may clot inside the gallbladder, resulting in gallbladder distension and possibly 
perforation into the abdomen. The patient may then present with peritonitis. The blood 
may also clot inside the common bile duct, resulting in obstructive symptoms. Finally, the 
blood may enter into the bowel lumen, with subsequent hematemesis or melena. The 
patient in this case did have hemorrhage into the gallbladder and peritoneal cavity but did 
not present with frank peritonitis. This is likely due to the fact that there was no gross 
bilious contamination of the abdomen and the blood was contained to the right upper 
quadrant. The cystic duct was completely obstructed, preventing hemorrhage into the 
intestinal lumen. Thus our patient did not experience hematemesis or melena as often 
occurs with hemorrhage into the biliary tract. 
The bleeding our patient experienced may have been exacerbated by cilostazol and 
aspirin therapy. Cilostazol is a phosphodiesterase inhibitor which decreases platelet 
aggregation. It is used in a variety of settings, including lower extremity claudication, after 
coronary stent placement, or cerebrovascular accident prevention. Cilostazol may offer 
chronotropic benefit in the treatment of patients with bradyarrhythmia [6]. Results of  
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investigation into the effect of cilostazol on hemostasis have been mixed, with at least one 
study demonstrating prolonged bleeding [7], while another failed to show a similar effect 
[8]. Platelet counts have not been found to be adversely affected [9]. Aspirin, on the other 
hand, has been shown clearly to prolong bleeding time and affect platelet aggregation [8, 
10, 11]. 
The treatment of hemorrhagic cholecystitis is cholecystectomy, or alternatively 
cholecystostomy in selected patients. As in our patient’s case, with intensive perioperative 
care, even patients of advanced age with multiple significant medical comorbidities can be 
successfully treated surgically. We are certainly thankful our 91-year-old patient 
ultimately recovered and was discharged after extensive efforts on the part of our medical 
and surgical services, but realize that this may not always be the case. Cholecystostomy 
should be reserved for those patients too unstable for the operating room and in whom 
adequate drainage can be accomplished. 
Conclusion 
Our patient experienced hemorrhagic cholecystitis as a rare complication of acute 
cholecystitis. While impossible to prove definitively, it is reasonable to suggest that 
treatment with aspirin and cilostazol contributed to the degree of hemorrhage. To our 
knowledge, this is the first report of hemorrhagic cholecystitis associated with these drugs. 
 
 
 
 
 
Fig. 1. Arterial phase contrast CT scan of the abdomen. The asterisk marks the mixed-density 
hemorrhagic fluid within the gallbladder (65 Hounsfield units). 
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Fig. 2. Intraoperative photo demonstrating a tense, distended gallbladder and focal hemorrhage of the 
gallbladder wall. 
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